Overall, TN-401 or AAV9:mPkp2 treatment supported a dose-dependent efficacy in improving ARVC phenotypes in Pkp2-cKO mouse model of ARVC. Here, PKP2 is linked to arrhythmogenic right ventricular cardiomyopathy.